Navigation Links
Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
Date:10/17/2007

e treatment of platinum-resistant or -refractory SCLC in nearly a decade.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead product candidate, is a new generation platinum therapy with an improved safety profile. Picoplatin is designed to overcome and prevent platinum resistance associated with chemotherapy in solid tumors. Intravenous picoplatin is currently being studied in clinical trials for the treatment of small cell lung, colorectal and hormone-refractory prostate cancer, and oral picoplatin is in a clinical trial in solid tumors. As part of the Company's strategic goal of building a diverse oncology pipeline, the Company is collaborating with The Scripps Research Institute on the discovery of novel, small-molecule, multi-targeted protein kinase inhibitors. For additional information please visit http://www.poniard.com.

This release contains forward-looking statements, including statements regarding the Company's business objectives and strategic goals, drug development plans, and the efficacy of its products in development. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the Company's research and development activities; the results of pre-clinical and clinical testing; the receipt and timing of required regulatory approvals; the market's acceptance of the Company's proposed products; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; competition from third parties; the Company's ability to preserve and protect intellectual property rights; the Company's dependence on third-party manufacturers an
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Speaker announces business members of IT Task Force
4. Doyle announces technology tax credits for Berbee
5. Doyle announces new energy, global warming policies
6. Doyle announces $80M renewable energy strategy
7. GE announces first installation of Discovery VCT
8. UWM announces winners of RGI awards
9. Third Wave announces two senior management appointments
10. Mirus announces new method for making antibodies
11. Merge announces sofware updates, upcoming acquisition

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...EGO, Nov. 20 Veridiam (www.veridia...d-size company category at the 2009 Workplace Exce... Diego Society for Human Resources Management and ...es practices. ,, Veridiam was one of nine winne... companies, honored at the recent awards ceremony....
(Date:11/20/2009)... METTLER TOLEDO recently announced that a ...timization Using At-Line Particle Characterization...n this webinar, the application of in situ particl...gn space and optimize a series of roller compactio...d roller compaction forces. , ...
(Date:11/19/2009)...LT, N.Y., Nov. 19 Dr. Mate Hidvegi... responds to a press release issued on November 17...pany for making false and self-serving statements ..., Dr. Hidvegi stated from his office in Budapes...arch on Avemar does not apply to AveULTRA, www.a...
(Date:11/19/2009)... MUNSTER, Germany, November 19 MON...on November 16th, 2009 Flibanserin in the,indicati...in Parkinson,s,disease for orphan drug status desi... Levodopa-induced dyskinesia is a complication of ... a serious burden to some of those,affected, since...
Breaking Biology Technology:Veridiam Wins Workplace Excellence Crystal Award in Mid-Size Company Category 2Roller Compaction Process Optimization Using At-Line Particle Characterization 2American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor 2MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2
..., N.J., April 4, 2008 Pharmasset,Inc. (Nasdaq: V...ms,Hepatitis C Conference being held on April 9, 2...er Price, Pharmasset,s Chief Executive Officer, wi...nd preclinical hepatitis C,virus (HCV) programs at... of Mr. Price,s overview via the,internet, log on ...
...nce Call Scheduled Friday, April 4, 2008 at 8:30 a...hts:, - 2007 pro forma consolidated net sales incr... $317.2 million, - Provided 2008 guidance: ... of $28 million to $30 million, -...3,800 at year-end 2007, - Established pharmacy o...
..., April 3, 2008 ADVENTRX,Pharmaceuticals, Inc. (A...ember of the Company,s Board of Directors, has joi...ly created position, and Chief Financial,Officer. ... with the,Company,s Chief Executive Officer and Pr..., help oversee internal execution of that strategy...
Other Biology Technology:Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th 2Chem Rx Corporation Reports Full Year 2007 Financial Results 2Chem Rx Corporation Reports Full Year 2007 Financial Results 3Chem Rx Corporation Reports Full Year 2007 Financial Results 4Chem Rx Corporation Reports Full Year 2007 Financial Results 5Chem Rx Corporation Reports Full Year 2007 Financial Results 6Chem Rx Corporation Reports Full Year 2007 Financial Results 7Chem Rx Corporation Reports Full Year 2007 Financial Results 8Chem Rx Corporation Reports Full Year 2007 Financial Results 9Chem Rx Corporation Reports Full Year 2007 Financial Results 10Chem Rx Corporation Reports Full Year 2007 Financial Results 11Chem Rx Corporation Reports Full Year 2007 Financial Results 12Chem Rx Corporation Reports Full Year 2007 Financial Results 13Chem Rx Corporation Reports Full Year 2007 Financial Results 14Chem Rx Corporation Reports Full Year 2007 Financial Results 15ADVENTRX Creates Executive Vice President Position and Announces New Chief Financial Officer 2ADVENTRX Creates Executive Vice President Position and Announces New Chief Financial Officer 3ADVENTRX Creates Executive Vice President Position and Announces New Chief Financial Officer 4
(Date:11/19/2009)...han 2: The offspring of two inbred strains tend to...ing the gene-level variability that leads to this ...uld boost our ability to custom-tailor crops for s...uman consumption or high glucose content for bioma...A sequence of the common corn strain B73, Universi...
(Date:11/19/2009)...ewswire-FirstCall/ -- BIO-key International, Inc. ...ublic safety and finger-based biometric identifica...lder Meeting held today was adjourned without any ...t. ,, (Logo: http://www.newscom.com/cgi-bin/pr...99.3% of the 35 million votes cast voted in favor ...
(Date:11/19/2009)...son, T. Ming Chu Professor of Biochemistry and Mol...veling how regulatory proteins control the product.... Working with collaborators including Drs. Mitche... Philadelphia, they focused specifically on the co...ocytes). These cells contain large amounts of hemo...
Breaking Biology News(10 mins):U of M plant scientist uncovers clues to yield-boosting quirks of corn genome 2BIO-key(R) Provides Update to Special Shareholder Meeting 2BIO-key(R) Provides Update to Special Shareholder Meeting 3New research into the mechanisms of gene regulation 2New research into the mechanisms of gene regulation 3New research into the mechanisms of gene regulation 4New research into the mechanisms of gene regulation 5ReBuilder Medical Technologies Inc Announces Second Quarter 2009 Profits up 100 25 55535 1ReBuilder Medical Technologies Inc Announces Second Quarter 2009 Profits up 100 25 55535 2Caraco Pharmaceutical Laboratories Ltd Announces Reversal of Summary Judgment in Ultracet 28R 29 ANDA Patent Litigation 55531 1Caraco Pharmaceutical Laboratories Ltd Announces Reversal of Summary Judgment in Ultracet 28R 29 ANDA Patent Litigation 55531 2M TEC Announces Leadership Changes and a Commitment to Serving as Innovators in the Medical Transcription Industrys Evolution 55528 1M TEC Announces Leadership Changes and a Commitment to Serving as Innovators in the Medical Transcription Industrys Evolution 55528 2M TEC Announces Leadership Changes and a Commitment to Serving as Innovators in the Medical Transcription Industrys Evolution 55528 3
...lution Named the Winner in the Best Security ...UNNYVALE, Calif., Sept. 3 Fujitsu Computer Produc...ive computer products including,hard disk drives, ...unced,today that its PalmSecure palm vein authenti...ecurity Solution for Healthcare Category as part o...
...niversity of Texas Medical Branch at Galveston res... the process by which the Ebola Zaire virus infect... the deadly disease produced by the virus. , Ebol...r in its victims and inflicts mortality rates clos...ntiviral therapy has been developed against the vi...
...ped lists of places with the worst air pollution i...ve improved the situation, tiny particles called a...tists from UC San Diego and six other institutions...city to precisely identify aerosols that make up t... mix. , This forensic work will help to identify ...
Other Biology News:Fujitsu PalmSecure(TM) Wins Network Products Guide 2008 Reader Trust Award 2Fujitsu PalmSecure(TM) Wins Network Products Guide 2008 Reader Trust Award 3Scientists uncover Ebola cell-invasion strategy 2Smoke smudges Mexico City's air, chemists identify sources 2Smoke smudges Mexico City's air, chemists identify sources 3
Hoagland's No. 2 Basal Salt Mixture from Sigma-Aldrich
Iscove's Modified Dulbecco's Medium (IMDM) from Sigma-Aldrich
...00 Q TRAP(TM) LC/MS/MS System, a high performance ...trometer for the drug discovery, drug development ...ap (LIT) Technology from the leaders in mass spect...e analysis with the proven, high sensitivity quant...
Dulbecco's Modified Eagle's Medium - high glucose (DME) from Sigma-Aldrich
Biology Products: